AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves.

AZ also revealed that its long-serving head of R&D, Mene Pangalos, will retire at the start of 2024 and be replaced by Sharon Barr, who is currently senior vice president and head of R&D at Alexion.

AstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent symptomatic COVID-19 infection when given to healthy ...

AstraZeneca could receive up to $400 million from Takeda after approaching the company to jointly develop and market a new treatment for Parkinson’s disease (PD). The deal will be centred on the ...

AstraZeneca has enlisted the help of Lilly in the development of its new Alzheimer's candidate AZD3293. The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies ...

Mene Pangalos, executive vice president, IMED Biotech Unit and Business Development, AZ, added: "MEDI1814 has a unique mechanism among antibodies in clinical development and could provide a ...

AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the disease transthyretin amyloidosis (ATTR). The deal is another sizeable ...

Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for heart ...

Mene Pangalos, executive vice president BioPharmaceuticals R&D, AstraZeneca said: “Fibrotic diseases such as idiopathic pulmonary fibrosis have significant impact on patients’ lives and new ...

AstraZeneca and the UK's Medical Research Council have unveiled a groundbreaking collaboration which will see them working hand-in-hand in a joint research facility in Cambridge in the UK.